Drug Profile
Recombinant aldesleukin - Medicenna Therapeutics
Alternative Names: Empowered Cytokines™; IL-2 Superkine; MDNA 109 superkine; MDNA-109; Superkines™Latest Information Update: 28 Aug 2023
Price :
$50
*
At a glance
- Originator Stanford University
- Developer Medicenna Therapeutics; Stanford University; University of Montreal
- Class Antiallergics; Antihyperglycaemics; Antineoplastics; Immunotherapies; Interleukins; Mood stabilisers; Recombinant proteins
- Mechanism of Action Interleukin-2 receptor beta subunit agonists; Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Malignant melanoma; Solid tumours
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for preclinical development in Solid-tumours in USA (SC)
- 28 Jul 2022 No recent reports of development identified for preclinical development in Malignant-melanoma in USA (SC)
- 28 Jan 2021 No recent reports of development identified for preclinical development in Cancer in USA